Grünenthal is guided by its vision of a world free of pain. As a global leader in pain research and development, we are passionate about exploring innovative treatment options that have the potential to meaningfully improve the lives of patients around the world. Every day, Grünenthal’s scientists use their deep expertise to reimagine the future of pain management.
Executing our strategy, we focus our R&D efforts on pain, epilepsy, pruritus and neurodegenerative disorders - areas of high unmet medical need. We take a holistic approach to pursuing breakthrough treatments for these conditions – and explore all possible technologies and modalities.
This enables us to pursue our priorities with a solution-agnostic mindset. We focus our in-house capabilities on critical and differentiating areas such as target identification, with a strong emphasis on human and clinical validation, as well as translational science and disease understanding. While focusing on these specific critical success factors, we can cover every step in the development of an innovative medicine. At the same time, we are committed to entering strategic partnerships with innovative players from across industry and academia who share our passion for shaping the field and fostering the development of meaningful therapies.
